Physician profile
John C Arrabal
NPI 1295727063
$2,922.41
in general payments reported to CMS, 2019-2025
28 companies · $340 in 2025
The $340 reported for 2025 was more than what 78% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $444 · 2021: $685 · 2022: $403 · 2023: $376 · 2024: $398 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,094 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,094.25 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $704.89 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $384.67 | 2019-2024 | Mounjaro |
| Exact Sciences Corporation | $274.45 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Teva Pharmaceuticals USA, INC. | $153.43 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.09 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $121.91 | 2019-2021 | |
| Glaxosmithkline, LLC. | $113.02 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $112.46 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $110.95 | 2022-2025 | Breztri, Farxiga, Fasenra |
| Astellas Pharma US INC | $108.26 | 2019-2025 | Veozah |
| Pfizer INC. | $76.87 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $72.98 | 2021-2025 | Rexulti |
| Amgen INC. | $58.78 | 2019-2024 | Prolia, Evenity, Repatha |
| Indivior INC. | $56.90 | 2020-2024 | Sublocade |
| Eisai INC. | $53.39 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $50.84 | 2021-2022 | |
| Lundbeck LLC | $50.30 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $45.97 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $44.31 | 2019-2021 | |
| Alkermes, INC. | $37.91 | 2022-2024 | Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.22 | 2025 | Caplyta |
| Radius Health, INC. | $25.96 | 2025 | Tymlos, Binosto |
| Mylan Specialty L.P. | $25.10 | 2021 | |
| Abbott Laboratories | $16.77 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.60 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.16 | 2022 | |
| Horizon Therapeutics Plc | $14.51 | 2023 | Krystexxa |
| Shire North American Group INC | $13.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Arrabal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.